Compare MGRC & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGRC | ARQT |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.9B |
| IPO Year | 1995 | 2020 |
| Metric | MGRC | ARQT |
|---|---|---|
| Price | $118.19 | $26.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $141.50 | $34.00 |
| AVG Volume (30 Days) | 141.3K | ★ 1.5M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $944,235,000.00 | $376,072,000.00 |
| Revenue This Year | $4.69 | $34.85 |
| Revenue Next Year | $4.81 | $29.39 |
| P/E Ratio | $106.58 | ★ N/A |
| Revenue Growth | 3.65 | ★ 91.34 |
| 52 Week Low | $94.99 | $13.06 |
| 52 Week High | $128.41 | $31.77 |
| Indicator | MGRC | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 67.08 | 71.86 |
| Support Level | $106.34 | $24.81 |
| Resistance Level | $118.28 | $27.26 |
| Average True Range (ATR) | 2.80 | 1.09 |
| MACD | 0.81 | 0.56 |
| Stochastic Oscillator | 97.64 | 87.88 |
McGrath RentCorp is a diversified business-to-business rental company with three rental divisions: relocatable modular buildings, portable storage containers, and electronic test equipment. It comprises four reportable business segments, namely the Modular Building segment (Mobile Modular), which generates maximum revenue; the Portable Storage segment (Portable Storage); the Electronic Test Equipment segment (TRS-RenTelco); and its classroom manufacturing business (Enviroplex), which sells modular buildings used as classrooms in California. The company generates its revenues mainly from the rental of its equipment under operating leases, with sales of equipment occurring in the normal course of business.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.